利利公司在首季度利超过2026年预期, 因为糖尿病和减肥药的销售强势. Lilly raised 2026 forecasts after beating first-quarter earnings on strong sales of diabetes and weight-loss drugs.

伊利莉升高了2026年的财务预测, 在超过第一季度的收益预期后. Eli Lilly raised its 2026 financial forecasts after beating first-quarter earnings expectations. 公司的糖尿病和减肥药品,包括Mounjaro和Zepbound在内的销量强推动了这一结果. Strong sales of its diabetes and weight-loss drugs, including Mounjaro and Zepbound, drove the results. 公司现在预计每股调整后的利将达到35.50至37美元,而收入为820亿到850亿美元. The company now expects $35.50 to $37.00 in adjusted profit per share on $82 billion to $85 billion in revenue.